Skip to main content
Premium Trial:

Request an Annual Quote

Cenix Adds Respiratory, Inflammatory Diseases to RNAi-Screening Deal With AstraZeneca

Premium

Cenix BioScience announced this week that it has signed multi-year deal to use its RNAi screening technology to discover novel drug targets for respiratory and inflammatory disease for AstraZeneca.

According to Cenix, the deal expands upon the companies' existing research arrangement in oncology, which was signed in 2008 (see GenomeWeb Daily News, 3/19/2008).

Under the new deal, Cenix will complete at least three projects for AstraZeneca that combine "multi-pass genome-scale screens for the discovery of novel [respiratory and inflammatory disease] target candidates with detailed validation analyses … using a number of primary human cell types," the company said.

Cenix will also adapt assays developed by AstraZeneca scientists to optimize their use in high-throughput RNAi studies in 384-well and/or 1,536-well formats.

Financial terms of the deal were not disclosed.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.